The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19
Open accessAbstract
Caly et al . 1 reported that ivermectin inhibited severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) in vitr o for up to 48 hours using ivermectin at 5 μM. The concentration resulting in 50% inhibition (IC 50 ; 2 µM) was > 35× higher than the maximum plasma concentration (C max ) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration‐time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 μg/kg), 60 mg, and 120 mg. Plasma total C max was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung C max after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC 50 , even for a dose level 10× higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC 50 in the lungs after single oral administration of the approved dose (predicted lung: 0.0873 µM) or at doses 10× higher that the approved dose administered orally (predicted lung: 0.820 µM). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro . Repurposing drugs for use in coronavirus disease 2019 (COVID‐19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Guzzo, C. A., Furtek, C. I., Porras, A. G., Chen, C., Tipping, R., Clineschmidt, C. M., Sciberras, D. G., Hsieh, J. Y., & Lasseter, K. C. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002237994 · Cited by 427
Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle
Lifschitz, A., Virkel, G., Sallovitz, J., Sutra, J. F., Galtier, P., Alvinerie, M., & Lanusse, C. (2000) · Veterinary Parasitology · doi:10.1016/s0304-4017(99)00175-2 · Cited by 190
Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat
Lespine, A., Alvinerie, M., Sutra, J., Pors, I., & Chartier, C. (2005) · Veterinary Parasitology · doi:10.1016/j.vetpar.2004.11.028 · Cited by 76
Duthaler, U., Suenderhauf, C., Karlsson, M. O., Hußner, J., zu Schwabedissen, H. E. M., Krähenbühl, S., & Hammann, F. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13840 · Cited by 46
Cited by
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
López-Medina, E., López, P., Hurtado, I. C., Dávalos, D. M., Ramirez, O., Martínez, E., Díazgranados, J. A., Oñate, J. M., Chavarriaga, H., Herrera, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.3071 · Cited by 376
Mycroft-West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Gandhi, N. S., Guimond, S. E., Miller, G. J., Meneghetti, M. C. Z., Nader, H. B., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721319 · Cited by 361
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001377 · Cited by 203
Metadata
- Authors
- Schmith, V. D., Zhou, J. (., & Lohmer, L. R. L.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2020-06-07
- Volume
- 108
- Issue
- 4
- Pages
- 762-765
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W3022811568
- Cited by
- 256
- References
- 6
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19. https://app.cochat.ai/papers/10.1002/cpt.1889
- The paper
- Schmith, V. D., Zhou, J. (., & Lohmer, L. R. L. (2020). The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.1889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.